"Australia Pharmaceuticals & Healthcare Report Q3 2014" Is Now Available at Fast Market Research
Pharmaceutical firms can expect swifter access to the Australian pharmaceutical market, following the scrapping of the Pharmaceutical Benefits Pricing Authority. Given that the development will not have a significant impact on how drugs are listed on the Pharmaceutical Benefits Scheme, we have maintained our pharmaceutical sales forecast. However, we highlight that any potential reform of the healthcare system is a downside risk to our forecasts.
View full press release